Athersys is a clinical stage biopharmaceutical company with a growing pipeline of highly differentiated, potential best in class therapeutics to treat significant and life-threatening diseases. The Company is engaged in the discovery and development of innovative new medicines designed to extend and enhance the quality of human life. Through the application of the proprietary technologies, Athersys has established a pipeline of therapeutic product development programs in multiple disease areas. This pipeline includes both stem cell therapy and pharmaceuticals.
Type | Public | |
Founded | 1995 | |
HQ | Cleveland, OH, US | Map |
Website | athersys.com |
USD | |
---|---|
Revenue (Q2, 2020) | 77.0k |
Market capitalization (22-Jan-2021) | 383.5m |
Closing stock price (22-Jan-2021) | 1.9 |
Cash (30-Jun-2020) | 80.7m |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 2.4m | 2.4m | 2.7m | 2.7m | 1.0m | 326.0k | 571.0k | 621.0k | 707.0k | 388.0k | 293.0k | 731.0k | 216.0k | 396.0k | 15.5m | 595.0k | 311.0k | 1.5m | 669.0k | 399.0k | 1.1m | 19.4m | 2.3m | 1.4m | 4.3m | (361.0k) | 77.0k | |
General and administrative expense | 1.4m | 1.1m | 1.3m | 1.2m | 1.1m | 1.5m | 1.6m | 1.5m | 1.8m | 1.8m | 1.7m | 1.9m | 1.9m | 1.9m | 2.0m | 2.0m | 1.8m | 2.1m | 2.2m | 2.1m | 2.7m | 2.4m | 2.6m | 3.1m | 2.9m | 3.0m | 3.5m | |
R&D expense | 4.4m | 4.3m | 5.6m | 5.0m | 4.1m | 5.6m | 5.1m | 4.7m | 6.2m | 5.8m | 5.8m | 5.7m | 5.3m | 5.1m | 6.7m | 5.8m | 5.3m | 5.6m | 4.6m | 5.4m | 8.9m | 10.1m | 9.5m | 11.4m | 11.1m | 8.9m | 12.1m | |
Operating expense total | 5.8m | 5.4m | 6.8m | 6.2m | 5.2m | 7.1m | 6.7m | 6.1m | 8.0m | 7.6m | 7.5m | 7.6m | 7.2m | 7.0m | 8.7m | 7.8m | 7.1m | 7.7m | 6.8m | 7.6m | 11.5m | 12.5m | 12.1m | 14.5m | 14.0m | 11.8m | 15.6m |
USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|---|---|---|---|---|
Cash | 8.8m | 25.5m | 31.9m | 26.1m | 23.0m | 14.8m | 29.3m | 51.1m | 35.0m |
Accounts Receivable | 689.0k | 490.0k | 520.0k | 694.0k | 361.0k | 598.0k | 739.0k | 262.0k | |
Prepaid Expenses | 304.0k | 286.0k | 387.0k | 427.0k | 429.0k | 1.1m | 1.8m | 1.2m | |
Current Assets | 14.4m | 26.3m | 32.9m | 27.2m | 23.8m | 16.3m | 31.2m | 57.8m | 37.2m |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 4.7m | 8.5m | 14.8m | 10.9m | 7.9m | 21.3m | 18.9m | 17.8m | 45.0m | 38.8m | 32.4m | 35.5m | 32.3m | 28.5m | 30.4m | 13.8m | 8.3m | 31.9m | 28.6m | 28.2m | 49.7m | 53.4m | 48.0m | 51.0m | 44.2m | 40.4m | 32.7m | 80.7m |
Accounts Receivable | 426.0k | 177.0k | 399.0k | 704.0k | 438.0k | 473.0k | 576.0k | 453.0k | 894.0k | 715.0k | 665.0k | 2.8m | 2.4m | 315.0k | 706.0k | 648.0k | 298.0k | 1.8m | 608.0k | 707.0k | 759.0k | 545.0k | 573.0k | |||||
Prepaid Expenses | 341.0k | 636.0k | 256.0k | 305.0k | 370.0k | 293.0k | 328.0k | 283.0k | 319.0k | 310.0k | 416.0k | 386.0k | 341.0k | 383.0k | 426.0k | 999.0k | 855.0k | 1.2m | 920.0k | 1.0m | 1.0m | 2.5m | 2.2m | 800.0k | 849.0k | 614.0k | 1.5m | 1.1m |
Current Assets | 21.9m | 17.5m | 17.0m | 12.0m | 8.7m | 22.1m | 19.8m | 18.6m | 46.2m | 39.8m | 33.4m | 38.7m | 35.1m | 29.2m | 31.5m | 25.7m | 20.5m | 34.9m | 30.1m | 30.0m | 58.4m | 69.5m | 62.6m | 54.3m | 48.1m | 42.5m | 34.5m | 81.9m |
USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|---|---|---|---|---|
Net Income | (13.7m) | (14.7m) | (30.7m) | (22.1m) | (16.4m) | (15.3m) | (32.2m) | (24.3m) | (44.6m) |
Depreciation and Amortization | 278.0k | 320.0k | 346.0k | 360.0k | 267.0k | 382.0k | 684.0k | 855.0k | 698.0k |
Accounts Payable | 983.0k | 201.0k | (196.0k) | 335.0k | (296.0k) | 2.4m | 1.5m | 4.3m | |
Cash From Operating Activities | (14.5m) | (17.7m) | (22.8m) | (25.8m) | (13.8m) | (10.9m) | (24.0m) | (13.3m) | (35.3m) |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (7.2m) | (9.5m) | (4.3m) | (8.0m) | (11.5m) | (9.4m) | (15.3m) | (20.9m) | (11.5m) | (10.8m) | (15.5m) | (12.5m) | (13.5m) | (20.0m) | 4.8m | (2.2m) | (8.2m) | (5.6m) | (11.9m) | (19.1m) | (10.2m) | (3.2m) | (13.0m) | (13.0m) | (22.6m) | (34.7m) | (15.6m) | (34.0m) |
Depreciation and Amortization | 127.0k | 202.0k | 75.0k | 155.0k | 236.0k | 85.0k | 171.0k | 257.0k | 89.0k | 182.0k | 272.0k | 70.0k | 136.0k | 201.0k | 68.0k | 134.0k | 248.0k | 164.0k | 331.0k | 508.0k | 186.0k | 376.0k | 573.0k | 184.0k | 341.0k | 508.0k | 190.0k | 412.0k |
Accounts Payable | 897.0k | 919.0k | (233.0k) | (132.0k) | (724.0k) | 501.0k | 30.0k | (890.0k) | (239.0k) | 11.0k | 295.0k | (678.0k) | (769.0k) | (529.0k) | 400.0k | 900.0k | 765.0k | 1.0m | (670.0k) | (1.0m) | 2.0m | 6.3m | 5.3m | 1.2m | 1.2m | 1.7m | 3.7m | |
Cash From Operating Activities | (5.8m) | (10.0m) | (5.4m) | (10.4m) | (14.0m) | (6.1m) | (12.5m) | (18.3m) | (7.3m) | (13.4m) | (19.7m) | 1.1m | (4.7m) | (8.4m) | 7.3m | 852.0k | (4.6m) | (5.4m) | (11.1m) | (17.9m) | (5.7m) | (1.3m) | (8.8m) | (5.5m) | (17.0m) | (25.2m) | (12.1m) | (24.8m) |
USD | Q2, 2011 |
---|---|
Financial Leverage | 1.8 x |
FY, 2016 | |
---|---|
Patent Applications | 170 |
Patents (US) | 21 |
Patents Issued | 200 |
Athersys has 2k Twitter Followers. The number of followers has decreased 0.3% month over month and increased 0.1% quarter over quarter
840
Tweets
751
Following
2k
Followers
4
Tweets last 30 days
21.3
Avg. likes per Tweet
100%
Tweets with engagement
When was Athersys founded?
Athersys was founded in 1995.
Who are Athersys key executives?
Athersys's key executives are Gil Van Bokkelen, Manal Morsy and Ivor MacLeod.
How many employees does Athersys have?
Athersys has 83 employees.
What is Athersys revenue?
Latest Athersys annual revenue is $5.6 m.
What is Athersys revenue per employee?
Latest Athersys revenue per employee is $67.9 k.
Who are Athersys competitors?
Competitors of Athersys include Seed Health, BeyondSpring and Rani Therapeutics.
Where is Athersys headquarters?
Athersys headquarters is located at 3201 Carnegie Ave, Cleveland.
Where are Athersys offices?
Athersys has offices in Cleveland and Canton.
How many offices does Athersys have?
Athersys has 2 offices.
Receive alerts for 300+ data fields across thousands of companies